/publications/issue/2007/2007-05/2007-05-6503

MYLAN BARRED FROM SELLING GENERIC TOPAMAX

Author:

A federal judge in New Jersey issued an injunction permanently barring Mylan Pharmaceuticals from selling generic topiramate tablets and capsules in the United States before September 26, 2008, the expiration date of the patent for TOPAMAX (topiramate) held by Ortho-McNeil Neurologics Inc. Mylan had challenged the validity of that patent and filed an abbreviated new drug application to market a generic version of the epilepsy drug. The branded manufacturer countered with a patent infringement complaint against Mylan and obtained a preliminary injunction against the generic firm last fall.